Marcus Vale: Genuine question before we get anywhere — have you ever been to Honduras for any reason?
Ben Okonkwo: I have not. Why?
Marcus Vale: Because as of June 23rd, 2026, per New Scientist, that is where you go if you want Minicircle to inject you with an unapproved klotho gene therapy. Honduras, Bahamas, Panama — take your pick. Offshore. No FDA clinical trial. Paying customers.
Ben Okonkwo: Hm. Okay. So — for anyone who just heard 'klotho' and blanked — one sentence: it's a protein your body makes, mainly in the kidneys, and it appears to slow cellular aging. Think of it as a dial. Low dial, faster wear. Minicircle's therapy — a non-integrating minicircle vector delivering the secreted isoform, s-KL — tries to turn that dial up.
Marcus Vale: In people. Without running it through the FDA first. Because — and this is the structural thing — the FDA doesn't recognize aging as a disease. There's no approval lane. So the offshore model isn't just bold. It's basically the only commercial option.
Ben Okonkwo: Which is either a very honest response to a broken regulatory framework, or — and I'm not ruling this out — a very convenient justification for skipping the safety work entirely.
Ben Okonkwo: Now — what's actually new, and I want to be precise about this — is Roig-Soriano, 2025. That's the study. AAV9-delivered secreted klotho, wild-type mice, treatment started at twelve months, which is roughly forty human years. Fifteen to twenty percent median lifespan extension. Muscle, bone, hippocampal neurogenesis — all improved. That is a genuinely strong preclinical signal. One study. One vector. One timing window.
Marcus Vale: Fifteen to twenty percent is not noise.
Ben Okonkwo: No, it's not. But — okay, here's what the headlines skip — that one study is the entire load-bearing preclinical fact Minicircle is moving from to human injection. There are no human trials. Zero published clinical data. And the human observational stuff people cite, the KL-VS heterozygous variant linked to better cognition, resistance to dementia — that's correlational. Those are people born with the variant. It says nothing about what happens when you artificially elevate klotho in someone who wasn't.
Marcus Vale: BioViva did the same move with telomerase. Offshore. No miracle stories followed.
Ben Okonkwo: Exactly — so this is a pattern, not a one-off. And the question I actually can't answer yet is whether klotho is a stronger signal than telomerase was, or whether we're just... earlier in the same hype cycle before the failure data propagates.
Marcus Vale: That's the bet, though, right? What experiment would have to fail for you to update?
Marcus Vale: The wrong take — and I keep hearing it — is that the non-integrating minicircle construct makes this meaningfully safer. Like, full stop safer. 'It doesn't edit the genome, therefore problem solved.'
Ben Okonkwo: Right, and — okay, that framing is doing a lot of work it shouldn't be doing.
Marcus Vale: It's not wrong, exactly. Non-integrating is genuinely different from the old integrating viral vectors. I'll give them that. But the safety frame is being misapplied.
Ben Okonkwo: Because the risk isn't integration. The risk is — actually, this is where the CityUHK Kidney International work becomes relevant. Klotho is an FGF23 co-receptor. That means chronically elevated klotho — which is exactly what a persistent minicircle vector produces — could throw phosphate and calcium homeostasis into territory no human study has mapped. The knockout mouse data showed severe phosphate retention, dramatic FGF23 elevation, undetectable serum s-KL. That's how tightly wound this system is. Dysregulate it the other direction and... we genuinely don't know.
Marcus Vale: So 'doesn't touch the genome' doesn't mean 'doesn't touch the mineral metabolism.'
Ben Okonkwo: Exactly. And Libella Gene Therapeutics ran paying patients through offshore telomerase trials on similar safety logic. No validated results.
Marcus Vale: Safer vector is not safe therapy. Those aren't the same bet.
Ben Okonkwo: And that's — I mean, that's actually the thing that keeps sitting with me. When someone flies to Honduras or the Bahamas and gets dosed by Minicircle, and something goes wrong — or nothing happens, or it works, whatever — who captures that? The FDLI flagged this explicitly: there's no FDA approval pathway for a therapy whose primary claim is healthspan extension, because aging isn't classified as a disease. So the regulated channel that would normally collect safety and efficacy data... it doesn't exist here. Not because Minicircle bypassed it. Because it literally isn't there.
Marcus Vale: And offshore dosing doesn't generate data that feeds back into anything. There's no trial registry. No IRB. The outcome — good, bad, null — just... disappears into a patient file in Panama.
Ben Okonkwo: Right. And wealthy medical tourists bear the immediate cost, fine, they chose it. But the safety and efficacy data that would actually protect everyone else — the people who can't afford a flight to the Bahamas — that never gets generated through any regulated channel. So the question I don't have an answer to: if Minicircle's paying patients are the de facto clinical trial, who decides when we've learned enough? And who pays if the answer is late?
